Browsing by Author "Dogan, Mutlu"

Now showing 1 - 7 of 7

Effectiveness of Bendamustine in Relapse or Refractory Lymphoma Cases: A Report From Turkey-The Turkish Oncology Group (TOG) Study.
(2017) Karadurmus, Nuri; Paydas, Semra; Ocal, Ramazan; Yildiz, Birol; Nayir, Erdinc; Dogan, Mutlu; Sumbul, Ahmet Taner; Surmeli, Zeki; Barista, Ibrahim; Ferhanoglu, Burhan; Ozgur, Gokhan; Erturk, Ismail; Ozaydin, Sukru; Petekkaya, Halil Ibrahim; Uskent, Necdet
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study
(2021) Karadurmus, Nuri; Paydas, Semra; Esin, Ece; Surmeli, Zeki Gokhan; Yildiz, Birol; Erturk, Ismail; Nayir, Erdinc; Dogan, Mutlu; Sumbul, Ahmet Taner; Barista, Ibrahim; Gurkan, Emel; Ocal, Ramazan; Ferhanoglu, Burhan; Ozgur, Gokhan; Karakas, Yusuf; Lacin, Sahin; Ozaydin, Sukru; Petekkaya, Halil İbrahim; Uskent, Necdet; 34336021
Introduction: We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey. Material and methods: In this retrospective study, we included relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity. Results: Ninety-nine patients with a median age of 59.8 years were included in the study. Eighty-one patients had NHL (follicular lymphoma: 10, diffuse large B- cell lymphoma: 27, mantle-cell lymphoma: 18, marginal zone lymphoma: 9, small lymphocytic lymphoma/chronic lymphocytic leukemia: 17) and 18 patients had HL. The patients had previously received a median of three lines of chemotherapy (range: 2-8) except autologous stem cell transplantation (ASCT); 19 patients (HL: 11, NHL: 8) had undergone ASCT. The objective response rate (ORR) was 74.3%, the complete response rate was 57% (= 53), and the partial response rate was 16.6% (= 19). The overall survival (OS) rate at 1 year was 74.6%. The progression-free survival (PFS) rate at 1 year was 62.5%. The most common side effects were lymphopenia, anemia and neutropenia. Side effects which were observed as grade 3 and higher levels were lymphopenia (14.1%), neutropenia (10.1%) and fatigue (7.1%). Conclusions: Objective response rate of bendamustine was found to be 74.3% in relapsed/refractory HL and NHL patients. It appears to be an effective option as a salvage treatment for patients who have previously received multiple lines of therapy.
Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience
(2014) Ozdemir, Nuriye; Dogan, Mutlu; Sendur, Mehmet Ali Nahit; Yazici, Ozan; Abali, Huseyin; Yazilitas, Dogan; Akinci, Muhammed Bulent; Aksoy, Sercan; Zengin, Nurullah; 25374196
Background: ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen in Hodgkin's lymphoma (HL). Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacy and safety of O as a part of ABOD in HL. Materials and Methods: Patients who had ABOD were enrolled. Stage I-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute Common Toxicity Criteria was used for toxicity. Results: Seventy-nine HL patients in our center between 2003 and 2007 were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their third decade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% for early relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4% for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients had autologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longer in early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02; respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT (p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicity-related deaths. Conclusions: ABOD seems to be effective with managable toxicity in HL, even in those with poor prognostic factors.
Efficacy of Trastuzumab-Based Therapy After Disease Progression on Lapatinib Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer Patients
(2014) Uncu, Dogan; Bayoglu, Ibrahim Vedat; Arslan, Ulku Yalcintas; Kucukoner, Mehmet; Artac, Mehmet; Koca, Dogan; Oguz, Arzu; Demirci, Umut; Arpaci, Erkan; Dogan, Mutlu; https://orcid.org/0000-0001-6512-6534; W-8004-2019
Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study-IMET, Protocol MF 14-02 (vol 29, pg 6327, 2022)
(2023) Soran, Atilla; Ozbas, Serdar; Ozcinar, Beyza; Isik, Arda; Dogan, Lutfi; Senol, Kazim; Dag, Ahmet; Karanlik, Hasan; Aytac, Ozgur; Cakmak, Guldeniz Karadeniz; Dalci, Kubilay; Dogan, Mutlu; Sezer, Yavuz Atakan; Gokgoz, Sehsuvar; Ozyar, Enis; Sezgin, Efe; 36484906
Intervention to hepatic and pulmonary METastases in breast cancer patients: Prospective, multi-institutional registry study-IMET; Protocol MF 14-02
(2022) Soran, Atilla; Ozbas, Serdar; Ozcinar, Beyza; Isik, Arda; Dogan, Lutfi; Senol, Kazim; Dag, Ahmet; Karanlik, Hasan; Aytac, Ozgur; Cakmak, Guldeniz Karadeniz; Dalci, Kubilay; Dogan, Mutlu; Sezer, Yavuz Atakan; Gokgoz, Mustafa Sehsuvar; Ozyar, Enis; Sezgin, Efe
The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study
(2022) Nazim Turhal, Serdar; Dogan, Mutlu; Esendagli, Guldal; Artac, Mehmet; Korkmaz, Levent; Coskun, Hasan Senol; Goker, Erdem; PerranYumuk, Fulden; Bilgetekin, Irem; Kose, Fatih; Uncu, Dogan; Kavgaci, Halil; Akyol, Gulen; Ozet, Ahmet; Yagci, Tamer; https://orcid.org/0000-0002-0156-5973; 33656690; G-4827-2016
Purpose Plexin C1 is a transmembrane receptor and plexin C1 overexpression might have role in carcinogenesis. Hepatocellular carcinoma (HCC) has poor prognosis because of its aggressive behavior and limited treatment options, especially in advanced stage. We recently documented that Plexin C1 was overexpressed in HCC. We aimed to evaluate the prognostic significance of Plexin C1 overexpression in HCC in the present study. Methods Plexin C1 overexpression was evaluated immunohistochemically on paraffin-embedded blocks of the HCC patients. Plexin C1 immunohistochemical staining was scored. Plexin C1 overexpression staining intensity and prevalence were used for plexin scale staining evaluation and plexin scores were estimated according this staining scale. Plexin C1 score and its association with survival and clinicopathological features was assessed. Results Sixty-seven HCC patients with adequate tissue for pathological evaluation were included. Median age was 63 years with male predominance (male to female ratio was 4.75 (n 57/12). Well-differentiated HCC (53.7%) patients had higher plexin C1 overexpression (p < 0.05). Median OS was 22.1 months. Patients with lower plexin C1 score (< 12) had shorter OS (17.5 vs 30.1 months, p = 0.036). Neutrophil count, GGT, and PNR (platelet/neutrophil ratio) had prognostic significance (p = 0.047, p = 0.018, and p = 0.045). Conclusion Plexin C1 overexpression is inversely correlated with grade in HCC. The patients with lower rate of Plexin C1 overexpression have worse survival outcome. It might be a prognostic factor in HCC.